We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio INDIANAPOLIS — Intravitreal aflibercept 8 ...
Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 1 extension study show EO2002, a nonsurgical cell therapy for corneal edema, ...
BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10) BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5) Maintenance or ...
Preplanned subgroup analysis of the MEAD study results showed that DEX implant 0.7 mg significantly improved visual and anatomic outcomes in patients with a history of previous medical or laser ...
DURAVYU 2.7mg demonstrated a +7.1 letter BCVA gain and 76-micron CST reduction at week 24, with a supplement-free rate of 73% versus 50% for eyes treated with aflibercept. These positive Phase 2 ...
Patients with retinal vein occlusion-related macular edema had a higher likelihood of blindness and low vision if they had low best-corrected visual acuity after 1 month of intravitreal treatment.
Fundus photographs of eyes with diabetic macular edema (DME) could be used to estimate best-corrected visual acuity (BCVA) when artificial intelligence examines the pictures. Best-corrected visual ...
FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback